Who Paid My Doc
Aliqopa
Drug Oncology
NDC 50419-385-01
General payments
$354,989
Research payments
$11,551,692
Through program year 2025, $354,989 in general payments and $11,551,692 in research payments were reported against Aliqopa (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
12 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $13,216 | 2 |
| 2024 | Research | $971,497 | 40 |
| 2023 | General | $2,465 | 7 |
| 2023 | Research | $760,223 | 70 |
| 2022 | General | $11,598 | 123 |
| 2022 | Research | $2,281,518 | 133 |
| 2021 | General | $23,379 | 260 |
| 2021 | Research | $1,437,666 | 22 |
| 2020 | General | $38,386 | 102 |
| 2020 | Research | $3,955,788 | 97 |
| 2019 | General | $279,161 | 2,191 |
| 2019 | Research | $2,131,784 | 73 |
Breakdown
The top 5 of 7 recipients; each share is of general payments naming this product in 2023.
Each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.
The top 5 of 7 states; each share is of general payments naming this product in 2023 where a state was reported.
Records
2,683 general · 437 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.